Tetracaine Hcl (tetracaine HCl/PF)

It isessential that the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

To produce local ophthalmic anesthesia, the usual dose is 1 drop topically in the eye(s) as needed.

Apply topically to the eye in the form of a 0.5% solution.

Not for injection or intraocular use; do not use intracamerally.

Administer under the direct supervision of a healthcare provider; not intended for patient self-administration.

Open package using standard aseptic technique. The dispenser may then be allowed to fall upon a sterile surface. The entire outer surface of the dispenser and its contents are sterile.

Each dispenser is for single patient use and does not contain a preservative; discard any unused portion.

Store at 2degreesC to 8degreesC; protect contents from light. Do not use if solution contains crystals, is cloudy, or discolored.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

None

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

Ocular adverse events: stinging, burning, conjunctival redness.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

Safety in the pediatric population has been demonstrated in clinical trials. Efficacy of tetracaine hydrochloride ophthalmic solution for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population.

There are no adequate and well-controlled studies with tetracaine hydrochloride ophthalmic solution in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature.

There are no data to assess whether tetracaine hydrochloride ophthalmic solution is excreted in human milk or to assess its effects on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for the drug and any potential adverse effects on the breastfed child from tetracaine or from the underlying maternal condition.

No overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution have been observed between elderly and younger patients.